Jan 29 (Reuters) - Valeant Pharmaceuticals International Inc said it would buy the worldwide rights of DendreonCorp 's Provenge drug and certain other assets through a "stalking horse" deal for $296...

cancer drug business. This news is not surprising, given the overhang from the $620 million in notes that were coming due in 2016, as the company continued to remain unprofitable despite Provenge sales of about $150 million last year.

cancer drug business. This news is not surprising given the overhang from the $620 million in notes that were coming due in 2016, as the company continued to remain unprofitable despite Provenge sales of about $150 million last year.